{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:27:18Z","timestamp":1785770838291,"version":"3.56.0"},"reference-count":206,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,18]]},"DOI":"10.1093\/ntr\/nty063","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T11:20:54Z","timestamp":1522236054000},"page":"357-369","source":"Crossref","is-referenced-by-count":38,"title":["Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders"],"prefix":"10.1093","volume":"21","author":[{"given":"Maryka","family":"Quik","sequence":"first","affiliation":[{"name":"Center for Health Sciences, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T","family":"Boyd","sequence":"additional","affiliation":[{"name":"University of Vermont Medical Center Neurology, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Bordia","sequence":"additional","affiliation":[{"name":"Center for Health Sciences, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara","family":"Perez","sequence":"additional","affiliation":[{"name":"Center for Health Sciences, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"key\n\t\t\t\t2019021810170064400_CIT0001","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ana.21481","article-title":"The basal ganglia in Parkinson\u2019s disease: Current concepts and unexplained observations","volume":"64","author":"Obeso","year":"2008","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0002","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2010.00131","article-title":"Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia","volume":"4","author":"Barroso-Chinea","year":"2010","journal-title":"Front Neuroanat"},{"issue":"9","key":"key\n\t\t\t\t2019021810170064400_CIT0003","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/mds.26199","article-title":"Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders","volume":"30","author":"Tremblay","year":"2015","journal-title":"Mov Disord"},{"issue":"35","key":"key\n\t\t\t\t2019021810170064400_CIT0004","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1523\/JNEUROSCI.0873-16.2016","article-title":"Involvement of striatal cholinergic interneurons and M1 and M4 muscarinic receptors in motor symptoms of Parkinson\u2019s disease","volume":"36","author":"Ztaou","year":"2016","journal-title":"J Neurosci"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0005","article-title":"Striatal cholinergic interneurons and Parkinson\u2019s disease","author":"Tanimura","year":"2017","journal-title":"Eur J Neurosci"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0006","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1523\/JNEUROSCI.4082-10.2011","article-title":"The distinct role of medium spiny neurons and cholinergic interneurons in the D\u2082\/A\u2082A receptor interaction in the striatum: Implications for Parkinson\u2019s disease","volume":"31","author":"Tozzi","year":"2011","journal-title":"J Neurosci"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0028-3908(03)00137-0","article-title":"Targeting striatal cholinergic interneurons in Parkinson\u2019s disease: Focus on metabotropic glutamate receptors","volume":"45","author":"Pisani","year":"2003","journal-title":"Neuropharmacology"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0009","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/17512433.2014.966812","article-title":"New treatments for the motor symptoms of Parkinson\u2019s disease","volume":"7","author":"Vijverman","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2014.05.004","article-title":"Role for the nicotinic cholinergic system in movement disorders; therapeutic implications","volume":"144","author":"Quik","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0011","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"\u03b16\u03b22* and \u03b14\u03b22* nicotinic acetylcholine receptors as drug targets for Parkinson\u2019s disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol Rev"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0012","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2015.10.039","article-title":"M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia","volume":"88","author":"Shen","year":"2015","journal-title":"Neuron"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12762","article-title":"Cholinergic interneurons in the dorsal and ventral striatum: Anatomical and functional considerations in normal and diseased conditions","volume":"1349","author":"Gonzales","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0014","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/mds.26300","article-title":"Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease","volume":"30","author":"Deffains","year":"2015","journal-title":"Mov Disord"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","article-title":"Cholinergic interneuron characteristics and nicotinic properties in the striatum","volume":"53","author":"Zhou","year":"2002","journal-title":"J Neurobiol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fnsyn.2014.00022","article-title":"Striatal cholinergic interneuron regulation and circuit effects","volume":"6","author":"Lim","year":"2014","journal-title":"Front Synaptic Neurosci"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0017","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnana.2011.00006","article-title":"Centrality of striatal cholinergic transmission in Basal Ganglia function","volume":"5","author":"Bonsi","year":"2011","journal-title":"Front Neuroanat"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pneurobio.2015.02.002","article-title":"Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia","volume":"127\u2013128","author":"Eskow Jaunarajs","year":"2015","journal-title":"Prog Neurobiol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0019","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0006-8993(98)01163-9","article-title":"Modulation of acetylcholine release via GABAA and GABAB receptors in rat striatum","volume":"816","author":"Ikarashi","year":"1999","journal-title":"Brain Res"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1046\/j.1471-4159.1994.62010070.x","article-title":"GABAergic modulation of striatal cholinergic interneurons: An in vivo microdialysis study","volume":"62","author":"DeBoer","year":"1994","journal-title":"J Neurochem"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0021","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1046\/j.0953-816x.2001.01750.x","article-title":"Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release","volume":"14","author":"Marti","year":"2001","journal-title":"Eur J Neurosci"},{"issue":"14","key":"key\n\t\t\t\t2019021810170064400_CIT0022","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1523\/JNEUROSCI.22-14-06176.2002","article-title":"Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons","volume":"22","author":"Pisani","year":"2002","journal-title":"J Neurosci"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720170037","article-title":"Role of dopamine D1 receptors in the control of striatal acetylcholine release by endogenous dopamine","volume":"22","author":"Acquas","year":"2001","journal-title":"Neurol Sci"},{"issue":"2\u20133","key":"key\n\t\t\t\t2019021810170064400_CIT0024","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0014-2999(90)90456-G","article-title":"Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat","volume":"186","author":"Damsma","year":"1990","journal-title":"Eur J Pharmacol"},{"issue":"3\u20134","key":"key\n\t\t\t\t2019021810170064400_CIT0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-2999(82)90204-7","article-title":"Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin","volume":"84","author":"Stoof","year":"1982","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0026","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjp.0701327","article-title":"D2 dopamine receptors and modulation of spontaneous acetylcholine (ACh) release from rat striatal synaptosomes","volume":"122","author":"Clos","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(90)90186-8","article-title":"Muscarinic receptor activation attenuates D2 dopamine receptor mediated inhibition of acetylcholine release in rat striatum: Indications for a common signal transduction pathway","volume":"37","author":"Drukarch","year":"1990","journal-title":"Neuroscience"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0028","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s002109900097","article-title":"Histaminergic neurons modulate acetylcholine release in the ventral striatum: Role of H3 histamine receptors","volume":"360","author":"Prast","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0029","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bjp.0703692","article-title":"Histamine depolarizes cholinergic interneurones in the rat striatum via a H(1)-receptor mediated action","volume":"131","author":"Bell","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0030","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","article-title":"Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: Implications for extrapyramidal side effects of serotonin reuptake inhibitors","volume":"32","author":"Bonsi","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0006-8993(81)90035-4","article-title":"Evidence of the modulatory role of serotonin in acetylcholine release from striatal interneurons","volume":"212","author":"Vizi","year":"1981","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.irn.2015.07.001","article-title":"Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine","volume":"124","author":"Dani","year":"2015","journal-title":"Int Rev Neurobiol"},{"issue":"Pt B","key":"key\n\t\t\t\t2019021810170064400_CIT0033","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuropharm.2014.11.003","article-title":"Diversity of native nicotinic receptor subtypes in mammalian brain","volume":"96","author":"Zoli","year":"2015","journal-title":"Neuropharmacology"},{"issue":"15","key":"key\n\t\t\t\t2019021810170064400_CIT0034","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1523\/JNEUROSCI.5095-09.2010","article-title":"Nicotinic acetylcholine receptors in the mesolimbic pathway: Primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement","volume":"30","author":"Gotti","year":"2010","journal-title":"J Neurosci"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0035","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1523\/JNEUROSCI.12-07-02765.1992","article-title":"Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment","volume":"12","author":"Marks","year":"1992","journal-title":"J Neurosci"},{"issue":"29","key":"key\n\t\t\t\t2019021810170064400_CIT0036","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1523\/JNEUROSCI.2056-10.2010","article-title":"Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors","volume":"30","author":"Drenan","year":"2010","journal-title":"J Neurosci"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0037","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bcp.2009.06.004","article-title":"Nicotinic acetylcholine receptors and the ascending dopamine pathways","volume":"78","author":"Livingstone","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0038","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/mol.58.2.312","article-title":"Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release","volume":"58","author":"Kaiser","year":"2000","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0039","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2009.05933.x","article-title":"Presynaptic nicotinic and D(2) receptors functionally interact on dopaminergic nerve endings of rat and mouse nucleus accumbens","author":"Grilli","year":"2009","journal-title":"J Neurochem"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/(SICI)1098-2396(199803)28:3<212::AID-SYN4>3.0.CO;2-D","article-title":"Nicotine increases stress-induced serotonin release by stimulating nicotinic acetylcholine receptor in rat striatum","volume":"28","author":"Takahashi","year":"1998","journal-title":"Synapse"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0041","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjp.0703989","article-title":"Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice","volume":"132","author":"Ryan","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0042","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0306-4522(01)00488-2","article-title":"Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture","volume":"109","author":"Jeyarasasingam","year":"2002","journal-title":"Neuroscience"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0043","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1460-9568.2007.05636.x","article-title":"Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action","volume":"26","author":"Park","year":"2007","journal-title":"Eur J Neurosci"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0044","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Exp Neurol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-120157","article-title":"The \u03b17 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice","volume":"3","author":"Stuckenholz","year":"2013","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0046","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","article-title":"Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors","volume":"338","author":"Huang","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","article-title":"TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque","volume":"73","author":"Johnston","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0048","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.113.207639","article-title":"Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson\u2019s disease","volume":"347","author":"Zhang","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0049","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2013.03.038","article-title":"\u03b14\u03b22 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats","volume":"71","author":"Quik","year":"2013","journal-title":"Neuropharmacology"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0051","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.25817","article-title":"ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease","volume":"29","author":"Zhang","year":"2014","journal-title":"Mov Disord"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0052","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neuropharm.2012.04.029","article-title":"Role for \u03b16 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice","volume":"63","author":"Quik","year":"2012","journal-title":"Neuropharmacology"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias; studies with parkinsonian nicotinic receptor knockout mice","author":"Quik","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0054","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.114.216283","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys","volume":"351","author":"Zhang","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"key\n\t\t\t\t2019021810170064400_CIT0055","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.26453","article-title":"\u03b17 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage","volume":"30","author":"Zhang","year":"2015","journal-title":"Mov Disord"},{"issue":"11","key":"key\n\t\t\t\t2019021810170064400_CIT0056","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.parkreldis.2014.05.007","article-title":"AQW051, a novel and selective nicotinic acetylcholine receptor \u03b17 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys","volume":"20","author":"Di Paolo","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0057","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/cap.2000.10.59","article-title":"Mecamylamine in Tourette\u2019s syndrome: a two-year retrospective case study","volume":"10","author":"Silver","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"key\n\t\t\t\t2019021810170064400_CIT0058","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","article-title":"Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette\u2019s disorder","volume":"40","author":"Silver","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0059","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuropharm.2013.05.016","article-title":"Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia","volume":"73","author":"Wecker","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0060","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1530-0277.2010.01371.x","article-title":"The role of nicotinic acetylcholine receptor (nAChR) \u03b17 subtype in the functional interaction between nicotine and ethanol in mouse cerebellum","volume":"35","author":"Taslim","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0061","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00702-013-1082-1","article-title":"Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets","volume":"121","author":"Jackson","year":"2014","journal-title":"J Neural Transm (Vienna)"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0062","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2016.02.019","article-title":"Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias","volume":"91","author":"Bordia","year":"2016","journal-title":"Neurobiol Dis"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0063","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1073\/pnas.1006511108","article-title":"Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice","volume":"108","author":"Ding","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0064","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2017.06.005","article-title":"Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia","volume":"295","author":"Scarduzio","year":"2017","journal-title":"Exp Neurol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.nbd.2014.01.016","article-title":"Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia","volume":"65","author":"Martella","year":"2014","journal-title":"Neurobiol Dis"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0066","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0067","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WCO.0000000000000113","article-title":"Treatment of early Parkinson\u2019s disease","volume":"27","author":"Pahwa","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0068","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-9158-4-3","article-title":"Treatment of the later stages of Parkinson\u2019s disease - pharmacological approaches now and in the future","volume":"4 June 25","author":"Jenner","year":"2015","journal-title":"Transl Neurodegener"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0069","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0000000000002509","article-title":"Levodopa therapy for Parkinson disease: a look backward and forward","volume":"86","author":"LeWitt","year":"2016","journal-title":"Neurology"},{"issue":"18","key":"key\n\t\t\t\t2019021810170064400_CIT0070","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1080\/14656566.2016.1254189","article-title":"Pharmacotherapies for Parkinson\u2019s disease symptoms related to cholinergic degeneration","volume":"17","author":"Perez-Lloret","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0071","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"86","author":"Pagano","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0072","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jnnp.29.3.214","article-title":"Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor","volume":"29","author":"Marshall","year":"1966","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"key\n\t\t\t\t2019021810170064400_CIT0073","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0022-510X(93)90150-W","article-title":"Effects of smoking in patients with early-onset Parkinson\u2019s disease","volume":"117","author":"Ishikawa","year":"1993","journal-title":"J Neurol Sci"},{"issue":"1\u20133","key":"key\n\t\t\t\t2019021810170064400_CIT0074","first-page":"274","article-title":"The effects of nicotine on Parkinson\u2019s disease","volume":"43","author":"Kelton","year":"2000","journal-title":"Brain Cogn"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0075","first-page":"33","article-title":"Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism","volume":"51","author":"Mitsuoka","year":"2002","journal-title":"Hiroshima J Med Sci"},{"issue":"12","key":"key\n\t\t\t\t2019021810170064400_CIT0076","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1468-1331.2007.01949.x","article-title":"Chronic high dose transdermal nicotine in Parkinson\u2019s disease: an open trial","volume":"14","author":"Villafane","year":"2007","journal-title":"Eur J Neurol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0077","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.21177","article-title":"Smoking-responsive juvenile-onset Parkinsonism","volume":"22","author":"Hanagasi","year":"2007","journal-title":"Mov Disord"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0078","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02245195","article-title":"The short-term effect of nicotine chewing gum in patients with Parkinson\u2019s disease","volume":"117","author":"Clemens","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0079","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.57.6.1032","article-title":"Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study","volume":"57","author":"Vieregge","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/01.wnl.0000196466.99381.5c","article-title":"Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease","volume":"66","author":"Shoulson","year":"2006","journal-title":"Neurology"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0081","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/1531-8257(199911)14:6<1011::AID-MDS1016>3.0.CO;2-F","article-title":"Worsening of motor performance in patients with Parkinson\u2019s disease following transdermal nicotine administration","volume":"14","author":"Ebersbach","year":"1999","journal-title":"Mov Disord"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0082","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ene.13474","article-title":"High-dose transdermal nicotine in Parkinson\u2019s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study","volume":"25","author":"Villafane","year":"2018","journal-title":"Eur J Neurol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0083","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson\u2019s disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0084","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann Neurol"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce","year":"2012","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0086","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","article-title":"Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence","volume":"26","author":"Wirdefeldt","year":"2011","journal-title":"Eur J Epidemiol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0087","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1002\/mds.22721","article-title":"Advances in environmental epidemiology","volume":"25","author":"Tanner","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0088","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mds.24012","article-title":"Environmental tobacco smoke and Parkinson\u2019s disease","volume":"27","author":"Searles Nielsen","year":"2012","journal-title":"Mov Disord"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0089","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/WCO.0b013e3283050461","article-title":"Update in the epidemiology of Parkinson\u2019s disease","volume":"21","author":"Elbaz","year":"2008","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.58.4.581","article-title":"Smoking and Parkinson\u2019s disease in twins","volume":"58","author":"Tanner","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0091","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tips.2007.03.001","article-title":"Nicotine neuroprotection against nigrostriatal damage: importance of the animal model","volume":"28","author":"Quik","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0092","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mds.25028","article-title":"Nicotine as a potential neuroprotective agent for Parkinson\u2019s disease","volume":"27","author":"Quik","year":"2012","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0093","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog Neurobiol"},{"issue":"11","key":"key\n\t\t\t\t2019021810170064400_CIT0094","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/mds.26362","article-title":"New treatments for levodopa-induced motor complications","volume":"30","author":"Rascol","year":"2015","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0095","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson\u2019s disease and L-dopa induced dyskinesia","volume":"18","author":"Iravani","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0096","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0097","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0098","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov Disord"},{"issue":"12","key":"key\n\t\t\t\t2019021810170064400_CIT0099","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov Disord"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s13311-014-0274-1","article-title":"Deep brain stimulation for movement disorders","volume":"11","author":"Larson","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"11","key":"key\n\t\t\t\t2019021810170064400_CIT0101","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00415-014-7254-6","article-title":"Deep brain stimulation in Parkinson\u2019s disease: meta-analysis of randomized controlled trials","volume":"261","author":"Perestelo-P\u00e9rez","year":"2014","journal-title":"J Neurol"},{"issue":"12","key":"key\n\t\t\t\t2019021810170064400_CIT0102","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/jnnp-2013-306907","article-title":"Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson\u2019s disease using an MRI-guided and MRI-verified approach","volume":"85","author":"Aviles-Olmos","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","article-title":"L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmissioN","volume":"5","author":"Feyder","year":"2011","journal-title":"Front Behav Neurosci"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann Neurol"},{"issue":"9","key":"key\n\t\t\t\t2019021810170064400_CIT0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.biopsych.2013.05.006","article-title":"L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice","volume":"75","author":"Su\u00e1rez","year":"2014","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0106","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","article-title":"Molecular mechanisms underlying levodopa-induced dyskinesia","volume":"23","author":"Calabresi","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0107","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog Neurobiol"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0108","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/14728214.2014.955014","article-title":"Emerging drugs for levodopa-induced dyskinesia","volume":"19","author":"Al Dakheel","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0109","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1523\/JNEUROSCI.2888-13.2014","article-title":"Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice","volume":"34","author":"Won","year":"2014","journal-title":"J Neurosci"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0110","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.109.162396","article-title":"Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization","volume":"333","author":"Bordia","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"key\n\t\t\t\t2019021810170064400_CIT0111","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25594","article-title":"Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease","volume":"28","author":"Quik","year":"2013","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0112","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2012.09.006","article-title":"Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function","volume":"50","author":"Quik","year":"2013","journal-title":"Neurobiol Dis"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0113","first-page":"137","article-title":"Potential of AZD1446, a novel nicotinic agonist, for the treatment of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"43","author":"Mather","year":"2014","journal-title":"Society for Neuroscience Abstr"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0114","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pneurobio.2007.12.005","article-title":"It is not \u201ceither\/or\u201d: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood","volume":"84","author":"Picciotto","year":"2008","journal-title":"Prog Neurobiol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.108.145292","article-title":"Desensitization of nicotinic acetylcholine receptors as a strategy for drug development","volume":"328","author":"Buccafusco","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"17","key":"key\n\t\t\t\t2019021810170064400_CIT0116","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1074\/jbc.M008035200","article-title":"Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity","volume":"276","author":"Kihara","year":"2001","journal-title":"J Biol Chem"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0117","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(00)01100-8","article-title":"Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity","volume":"49","author":"Shimohama","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0118","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1471-4159.2005.03223.x","article-title":"Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells","volume":"94","author":"Ren","year":"2005","journal-title":"J Neurochem"},{"issue":"12","key":"key\n\t\t\t\t2019021810170064400_CIT0119","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1096\/fj.06-6191com","article-title":"Receptor-mediated tobacco toxicity: Cooperation of the Ras\/Raf-1\/MEK1\/ERK and JAK-2\/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes","volume":"20","author":"Arredondo","year":"2006","journal-title":"FASEB J"},{"issue":"47","key":"key\n\t\t\t\t2019021810170064400_CIT0120","doi-asserted-by":"crossref","first-page":"44920","DOI":"10.1074\/jbc.M204610200","article-title":"Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid","volume":"277","author":"Shaw","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jcb.21013","article-title":"ERK \u00bd signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons","volume":"100","author":"Toborek","year":"2007","journal-title":"J Cell Biochem"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0122","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.neuroscience.2007.05.013","article-title":"The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice","volume":"148","author":"Ren","year":"2007","journal-title":"Neuroscience"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0123","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuint.2009.09.011","article-title":"Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation","volume":"56","author":"Tyagi","year":"2010","journal-title":"Neurochem Int"},{"issue":"11","key":"key\n\t\t\t\t2019021810170064400_CIT0124","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.freeradbiomed.2010.09.017","article-title":"Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via \u03b17 nicotinic receptors linked to a Jak2\/Akt\/HO-1 signaling pathway","volume":"49","author":"Parada","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/B978-0-444-52014-2.00042-2","article-title":"Typical and atypical neuroleptics","volume":"100","author":"Gershanik","year":"2011","journal-title":"Handb Clin Neurol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0126","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0127","first-page":"141","article-title":"Role of atypical antipsychotics in rapid cycling bipolar disorder: A review of the literature","volume":"23","author":"Zupancic","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0128","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0129","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/00325481.2015.1074031","article-title":"Identification and management of tardive dyskinesia: A case series and literature review","volume":"127","author":"Khouzam","year":"2015","journal-title":"Postgrad Med"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0130","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0131","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2 receptors as treatment targets in schizophrenia","volume":"4","author":"Seeman","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0132","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","article-title":"The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats","volume":"165","author":"Turrone","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0133","doi-asserted-by":"crossref","DOI":"10.1517\/14728214.2015.1050376","article-title":"Emerging drugs for antipsychotic-induced tardive dyskinesia: Investigational drugs in Phase II and Phase III clinical trials","author":"Lockwood","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0134","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"Br J Psychiatry"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0136","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0137","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0138","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: Therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"11","key":"key\n\t\t\t\t2019021810170064400_CIT0139","doi-asserted-by":"crossref","first-page":"e48665","DOI":"10.1371\/journal.pone.0048665","article-title":"Low dose nicotine and antagonism of \u03b22 subunit containing nicotinic acetylcholine receptors have similar effects on affective behavior in mice","volume":"7","author":"Anderson","year":"2012","journal-title":"PLoS One"},{"issue":"21","key":"key\n\t\t\t\t2019021810170064400_CIT0140","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0141","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.111.189100","article-title":"Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats","volume":"340","author":"Bordia","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0142","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.111.185306","article-title":"Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor","volume":"339","author":"Lummis","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"28","key":"key\n\t\t\t\t2019021810170064400_CIT0143","doi-asserted-by":"crossref","first-page":"9574","DOI":"10.1523\/JNEUROSCI.1196-12.2012","article-title":"Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: Comparison of the subthalamic and entopeduncular nuclei","volume":"32","author":"Creed","year":"2012","journal-title":"J Neurosci"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0144","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbr.2011.01.025","article-title":"Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats","volume":"219","author":"Creed-Carson","year":"2011","journal-title":"Behav Brain Res"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-2999(01)01284-5","article-title":"Effect of 5-HT1A and 5-HT2A\/2C receptor modulation on neuroleptic-induced vacuous chewing movements","volume":"428","author":"Naidu","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0146","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neubiorev.2011.06.007","article-title":"Smoking, quitting, and psychiatric disease: A review","volume":"36","author":"Aubin","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0147","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1055\/s-2008-1081463","article-title":"The molecular and cellular neurobiology of nicotine abuse in schizophrenia","volume":"41","author":"Mobascher","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0148","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0006-3223(96)00289-2","article-title":"Cigarette smoking is associated with abnormal involuntary movements in the general male population\u2013a study of men born in 1933","volume":"41","author":"Nilsson","year":"1997","journal-title":"Biol Psychiatry"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0149","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0006-3223(87)90131-4","article-title":"Nicotine exposure and tardive dyskinesia","volume":"22","author":"Yassa","year":"1987","journal-title":"Biol Psychiatry"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0006-3223(91)90163-G","article-title":"Smoking and movement disorders in psychiatric patients","volume":"30","author":"Menza","year":"1991","journal-title":"Biol Psychiatry"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0151","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.pnpbp.2011.06.006","article-title":"Smoking and tardive dyskinesia in male patients with chronic schizophrenia","volume":"35","author":"Zhang","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0152","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.expneurol.2016.09.009","article-title":"Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia","volume":"286","author":"Bordia","year":"2016","journal-title":"Exp Neurol"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0153","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2012.05.043","article-title":"Pharmacological treatment of tic disorders and Tourette Syndrome","volume":"68","author":"Roessner","year":"2013","journal-title":"Neuropharmacology"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0154","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-013-0979-z","article-title":"The pharmacology of Tourette syndrome","volume":"120","author":"Thomas","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0155","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/B978-0-12-411546-0.00015-9","article-title":"Emerging treatment strategies in Tourette syndrome: What\u2019s in the pipeline","volume":"112","author":"Termine","year":"2013","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0156","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14728214.10.2.365","article-title":"Emerging drugs in Tourette syndrome","volume":"10","author":"Silay","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0157","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-411546-0.00004-4","article-title":"Nondopaminergic neurotransmission in the pathophysiology of Tourette syndrome","volume":"112","author":"Udvardi","year":"2013","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0158","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1073\/pnas.1419533112","article-title":"Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome","volume":"112","author":"Xu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0159","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.biopsych.2014.07.018","article-title":"Transcriptome analysis of the human striatum in Tourette syndrome","volume":"79","author":"Lennington","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0753-3322(89)90186-8","article-title":"Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome","volume":"43","author":"Sanberg","year":"1989","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0161","first-page":"793","article-title":"Nicotine potentiation of haloperidol in reducing tic frequency in Tourette\u2019s disorder","volume":"148","author":"McConville","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"8936","key":"key\n\t\t\t\t2019021810170064400_CIT0162","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90388-3","article-title":"Longlasting improvement of Tourette\u2019s syndrome with transdermal nicotine","volume":"344","author":"Dursun","year":"1994","journal-title":"Lancet"},{"issue":"12","key":"key\n\t\t\t\t2019021810170064400_CIT0163","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/00004583-199612000-00015","article-title":"Case study: Long-term potentiation of neuroleptics with transdermal nicotine in Tourette\u2019s syndrome","volume":"35","author":"Silver","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0164","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/mehy.1997.0623","article-title":"Smoking, nicotine and psychiatric disorders: Evidence for therapeutic role, controversies and implications for future research","volume":"52","author":"Dursun","year":"1999","journal-title":"Med Hypotheses"},{"issue":"9","key":"key\n\t\t\t\t2019021810170064400_CIT0165","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4088\/JCP.v62n0908","article-title":"Transdermal nicotine and haloperidol in Tourette\u2019s disorder: A double-blind placebo-controlled study","volume":"62","author":"Silver","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0166","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clinthera.2008.01.010","article-title":"Donepezil use in children and adolescents with tics and attention-deficit\/hyperactivity disorder: An 18-week, single-center, dose-escalating, prospective, open-label study","volume":"30","author":"Cubo","year":"2008","journal-title":"Clin Ther"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0167","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.physbeh.2012.06.023","article-title":"Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette\u2019s, depression, and beyond","volume":"107","author":"Sanberg","year":"2012","journal-title":"Physiol Behav"},{"issue":"10","key":"key\n\t\t\t\t2019021810170064400_CIT0168","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(00)00945-8","article-title":"Comorbid bipolar disorder in Tourette\u2019s syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine)","volume":"48","author":"Shytle","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0169","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/mds.22564","article-title":"Effectiveness and safety of treatments for degenerative ataxias: A systematic review","volume":"24","author":"Trujillo-Mart\u00edn","year":"2009","journal-title":"Mov Disord"},{"issue":"3","key":"key\n\t\t\t\t2019021810170064400_CIT0170","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.31.3.288","article-title":"Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias","volume":"31","author":"Kark","year":"1981","journal-title":"Neurology"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0171","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1212\/WNL.27.1.70","article-title":"Physostigmine in familial ataxias","volume":"27","author":"Kark","year":"1977","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0172","first-page":"195","article-title":"Action of physostigmine on inherited ataxias","volume":"21","author":"Rodriguez-Budelli","year":"1978","journal-title":"Adv Neurol"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0173","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archneur.1997.00550160041013","article-title":"Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases","volume":"54","author":"Wessel","year":"1997","journal-title":"Arch Neurol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0174","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-510X(81)90162-3","article-title":"Choline chloride in the treatment of cerebellar and spinocerebellar ataxia","volume":"50","author":"Livingstone","year":"1981","journal-title":"J Neurol Sci"},{"issue":"12","key":"key\n\t\t\t\t2019021810170064400_CIT0175","first-page":"1568","article-title":"Use of choline in the treatment of ataxia associated with multiple sclerosis","volume":"121","author":"Blattel","year":"1979","journal-title":"Can Med Assoc J"},{"issue":"6149","key":"key\n\t\t\t\t2019021810170064400_CIT0176","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/bmj.2.6149.1403-a","article-title":"Oral choline in cerebellar ataxia","volume":"2","author":"Legg","year":"1978","journal-title":"Br Med J"},{"issue":"6190","key":"key\n\t\t\t\t2019021810170064400_CIT0177","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/bmj.2.6190.613","article-title":"Choline in hereditary ataxia","volume":"2","author":"Philcox","year":"1979","journal-title":"Br Med J"},{"issue":"6","key":"key\n\t\t\t\t2019021810170064400_CIT0178","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/WNF.0b013e31818736a9","article-title":"Treatment of ataxia and imbalance with varenicline (chantix): Report of 2 patients with spinocerebellar ataxia (types 3 and 14)","volume":"31","author":"Zesiewicz","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0179","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0404.2008.01070.x","article-title":"Treatment of imbalance with varenicline Chantix\u00ae: Report of a patient with fragile X tremor\/ataxia syndrome","volume":"119","author":"Zesiewicz","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CND.0b013e3181910074","article-title":"Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix)","volume":"10","author":"Zesiewicz","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"issue":"8","key":"key\n\t\t\t\t2019021810170064400_CIT0181","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","article-title":"A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3","volume":"78","author":"Zesiewicz","year":"2012","journal-title":"Neurology"},{"issue":"22","key":"key\n\t\t\t\t2019021810170064400_CIT0182","first-page":"2218","article-title":"A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3","volume":"79","author":"Connolly","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0183","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1530-0277.2006.00143.x","article-title":"Behavioral interaction between nicotine and ethanol: Possible modulation by mouse cerebellar glutamate","volume":"30","author":"Al-Rejaie","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0184","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuroscience.2008.08.046","article-title":"Attenuation of ethanol-induced ataxia by alpha(4)beta(2) nicotinic acetylcholine receptor subtype in mouse cerebellum: A functional interaction","volume":"157","author":"Taslim","year":"2008","journal-title":"Neuroscience"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0079-6123(08)62388-2","article-title":"Muscarinic acetylcholine receptor subtypes: Localization and structure\/function","volume":"98","author":"Brann","year":"1993","journal-title":"Prog Brain Res"},{"issue":"208","key":"key\n\t\t\t\t2019021810170064400_CIT0186","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-3-642-23274-9_10","article-title":"Muscarinic modulation of striatal function and circuitry","author":"Goldberg","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0187","first-page":"CD003735","article-title":"Anticholinergics for symptomatic management of Parkinson\u2019s disease","author":"Katzenschlager","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0188","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuropharm.2017.03.017","article-title":"M1muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons","volume":"118","author":"Lv","year":"2017","journal-title":"Neuropharmacology"},{"issue":"5 Pt 2","key":"key\n\t\t\t\t2019021810170064400_CIT0189","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1523\/JNEUROSCI.14-05-03351.1994","article-title":"Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: Light and electron microscopic immunocytochemistry using subtype-specific antibodies","volume":"14","author":"Hersch","year":"1994","journal-title":"J Neurosci"},{"issue":"15","key":"key\n\t\t\t\t2019021810170064400_CIT0190","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1523\/JNEUROSCI.22-15-06347.2002","article-title":"Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice","volume":"22","author":"Zhang","year":"2002","journal-title":"J Neurosci"},{"issue":"5-6","key":"key\n\t\t\t\t2019021810170064400_CIT0191","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.brainresbull.2012.08.009","article-title":"Modulation of acetylcholine release by cholecystokinin in striatum: Receptor specificity; role of dopaminergic neuronal activity","volume":"89","author":"Petkova-Kirova","year":"2012","journal-title":"Brain Res Bull"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0192","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1523\/JNEUROSCI.22-05-01709.2002","article-title":"Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice","volume":"22","author":"Zhang","year":"2002","journal-title":"J Neurosci"},{"issue":"24","key":"key\n\t\t\t\t2019021810170064400_CIT0193","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1523\/JNEUROSCI.1678-08.2008","article-title":"Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum","volume":"28","author":"Bonsi","year":"2008","journal-title":"J Neurosci"},{"issue":"22\u201323","key":"key\n\t\t\t\t2019021810170064400_CIT0194","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/S0024-3205(01)01056-6","article-title":"Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788","volume":"68","author":"Lachowicz","year":"2001","journal-title":"Life Sci"},{"issue":"9","key":"key\n\t\t\t\t2019021810170064400_CIT0195","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1523\/JNEUROSCI.5620-09.2010","article-title":"Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum","volume":"30","author":"Threlfell","year":"2010","journal-title":"J Neurosci"},{"issue":"7306","key":"key\n\t\t\t\t2019021810170064400_CIT0196","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nature09159","article-title":"Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry","volume":"466","author":"Kravitz","year":"2010","journal-title":"Nature"},{"issue":"4","key":"key\n\t\t\t\t2019021810170064400_CIT0197","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.celrep.2015.09.034","article-title":"Striatal cholinergic interneurons control motor behavior and basal ganglia function in experimental parkinsonism","volume":"13","author":"Maurice","year":"2015","journal-title":"Cell Rep"},{"issue":"2","key":"key\n\t\t\t\t2019021810170064400_CIT0198","doi-asserted-by":"crossref","first-page":"100","DOI":"10.17925\/USN.2011.07.02.100","article-title":"Advances in therapeutic options for gait and balance in Parkinson\u2019s disease","volume":"7","author":"Bohnen","year":"2011","journal-title":"US Neurol"},{"issue":"14","key":"key\n\t\t\t\t2019021810170064400_CIT0199","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/mds.23932","article-title":"The interplay of cholinergic function, attention, and falls in Parkinson\u2019s disease","volume":"26","author":"Yarnall","year":"2011","journal-title":"Mov Disord"},{"issue":"14","key":"key\n\t\t\t\t2019021810170064400_CIT0200","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2174\/1381612822666160127111848","article-title":"Regulation of gait and balance: The underappreciated role of neuronal nicotinic receptor agonists","volume":"22","author":"Young","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"14","key":"key\n\t\t\t\t2019021810170064400_CIT0201","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","article-title":"Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease","volume":"75","author":"Chung","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0202","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/jnc.13910","article-title":"Deletion of the vesicular acetylcholine transporter from pedunculopontine\/laterodorsal tegmental neurons modifies gait","volume":"140","author":"Janickova","year":"2017","journal-title":"J Neurochem"},{"issue":"5","key":"key\n\t\t\t\t2019021810170064400_CIT0203","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jnc.13899","article-title":"ExPPNing how acetylcholine improves gait in Parkinson\u2019s disease: An editorial highlight for \u2018deletion of the vesicular acetylcholine transporter from pedunculopontine\/laterodorsal tegmental neurons modifies gait\u2019","volume":"140","author":"Falkenburger","year":"2017","journal-title":"J Neurochem"},{"key":"key\n\t\t\t\t2019021810170064400_CIT0204","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/NDT.S30767","article-title":"Treatment of neurolept-induced tardive dyskinesia","volume":"9","author":"Jankelowitz","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"key\n\t\t\t\t2019021810170064400_CIT0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/pcn.12088","article-title":"Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function","volume":"68","author":"Ogino","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"issue":"7","key":"key\n\t\t\t\t2019021810170064400_CIT0206","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/mds.25552","article-title":"Medical treatment of dystonia","volume":"28","author":"Jankovic","year":"2013","journal-title":"Mov Disord"}],"container-title":["Nicotine &amp; Tobacco Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ntr\/article-pdf\/21\/3\/357\/27838333\/nty063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:59:30Z","timestamp":1660715970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ntr\/article\/21\/3\/357\/5075789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":206,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,8,17]]},"published-print":{"date-parts":[[2019,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ntr\/nty063","relation":{},"ISSN":["1462-2203","1469-994X"],"issn-type":[{"value":"1462-2203","type":"print"},{"value":"1469-994X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,8,17]]}}}